OncoMed Pharmaceuticals Inc
OncoMed Pharmaceuticals Inc is listed today as OncoMed: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2013 | $22 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
OncoMed Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Dec 2013).
SEC Form D · Dec 2013
The industry group it chose in its notices: Biotechnology.
SEC Form D · Dec 2013
That is all the official record says: OncoMed Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of OncoMed Pharmaceuticals Inc are on record.
Investors#
21 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Austin Gurney | Person | not stated | not stated | Held Series B and B-1 preferred stock (Form 3, 2013) | SEC Form 3 |
| GSK PLC | Fund or asset manager | not stated | not stated | Held Series B-2 and B-3 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| John A. Lewicki | Person | not stated | not stated | Held Series B and B-1 preferred stock (Form 3, 2013) | SEC Form 3 |
| LVP GP III, LLC | Other | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| LVP GP II, LLC | Other | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| LVP GP I, LLC | Other | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| LVP III Associates, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| LVP III Partners LP | Fund or asset manager | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| LVP Life Science Ventures III L.P. | Venture capital | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| LVP Life Science Ventures II, L.P. | Venture capital | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| LVP Life Science Ventures I, L.P. | Venture capital | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Lvpmc, LLC | Other | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Morgenthaler Management Partners VII, LLC | Fund or asset manager | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Morgenthaler Partners VII LP | Fund or asset manager | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Presidio Management Group VIII L L C | Fund or asset manager | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Timothy Hoey | Person | not stated | not stated | Held Series B and B-1 preferred stock (Form 3, 2013) | SEC Form 3 |
| US Venture Partners VIII L.P. | Venture capital | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Usvp Entrepreneur Partners VIII A L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Usvp Entrepreneur Partners VIII B L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Usvp VIII Affiliates Fund L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Vertical Group LP | Fund or asset manager | not stated | not stated | Held Series A, B and B-1 preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alicia J. Hager | Executive officer | Dec 2013 |
| Austin J. Gurney | Executive officer | Dec 2013 |
| Jakob A. Dupont | Executive officer | Dec 2013 |
| John A. Lewicki | Executive officer | Dec 2013 |
| Paul J. Hastings | Executive officer | Dec 2013 |
| Sunil A. Patel | Executive officer | Dec 2013 |
| Timothy J. Hoey | Executive officer | Dec 2013 |
| William D. Waddill | Executive officer | Dec 2013 |
| Deepa J. Pakianathan | Director | Dec 2013 |
| Denise J. Pollard-Knight | Director | Dec 2013 |
| Jack J. Lasersohn | Director | Dec 2013 |
| James J. Broderick | Director | Dec 2013 |
| Jim J. Woody | Director | Dec 2013 |
| Jonathan J. Root | Director | Dec 2013 |
| Larry J. Lasky | Director | Dec 2013 |
| Michael J. Wyzga | Director | Dec 2013 |
| Paul J. Hastings | Director | Dec 2013 |
| Terry J. Gould | Director | Dec 2013 |
About
Public American pharmaceutical company.